A safe, inexpensive, and easily accessible vitamin found at pharmacies and health food stores could lower the risk of the most common form of cancer. A study done at the University of Sydney — a region that knows a lot about sun exposure — found that a high dose of a form of vitamin B3, nicotinamide, can prevent up to a fourth of non-melanoma skin cancers.
Sun exposure is the primary cause of non-melanoma skin cancer. Every year over two million people are diagnosed with this skin cancer in the US. One in five people will be diagnosed with it in their lifetime. More new cases of skin cancer are diagnosed each year than breast, prostate, colon, and lung cancers combined, and the incidence continues to increase.
Over 380 people with a history of skin cancer took a nicotinamide pill twice daily for a year. Each had experienced at least two non-melanoma skin cancers in the last five years and was considered at high risk for developing more skin cancers. In those who took nicotinamide, the incidence of new non-melanoma skin cancers was reduced by 23 percent and that of pre-cancerous skin conditions was reduced by about 15 percent, compared to a group of people who took a placebo.
Nicotinamide was effective in preventing both types of carcinomas.
Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most common types of non-melanoma skin cancer. Unlike SCC which can spread throughout the body, BCCs rarely metastasize but can cause cosmetic problems since they commonly occur on the face. The study found that nicotinamide was effective in preventing both types of carcinomas.
Vitamin B3 is one of eight B vitamins. It is also known as niacin, and there are two forms of it — nicotinic acid and nicotinamide, the form used in the study. Side effects such as headaches, flushing and tingling of the skin, rash, and low blood pressure are often seen in people who take niacin or nicotinic acid. Nicotinamide doesn’t cause these side effects.
The cost of treating non-melanoma skin cancers in the US is $4.8 billion per year. Since nicotinamide is inexpensive and available over the counter, the findings from this study have the potential to substantially reduce this economic burden.
The study, published in the New England Journal of Medicine, was not designed to study the effect of nicotinamide in people who have never had skin cancer or whether the vitamin could decrease the risk of melanoma, so the findings do not apply to people in the general population who have never been diagnosed with skin cancer.